Rhumbline Advisers Mirati Therapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$41.99 - $62.38 $392,564 - $583,190	9,349 Added 18.02%	61,220 $3.6 Million
Q3 2023 Nov 09, 2023	BUY	$27.8 - $45.35 $11,787 - $19,228	424 Added 0.82%	51,871 $2.26 Million
Q2 2023 Aug 08, 2023	BUY	$36.13 - $49.49 $108,751 - $148,964	3,010 Added 6.21%	51,447 $1.86 Million
Q1 2023 May 11, 2023	SELL	$36.54 - $54.26 $29,853 - $44,330	-817 Reduced 1.66%	48,437 $1.8 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $127,565 - $304,834	3,091 Added 6.7%	49,254 $2.23 Million
Q3 2022 Nov 10, 2022	BUY	$59.5 - $86.7 $417,749 - $608,720	7,021 Added 17.94%	46,163 $3.22 Million
Q2 2022 Aug 11, 2022	BUY	$39.16 - $88.71 $141,289 - $320,065	3,608 Added 10.15%	39,142 $2.63 Million
Q1 2022 May 12, 2022	SELL	$75.82 - $150.97 $221,470 - $440,983	-2,921 Reduced 7.6%	35,534 $2.92 Million
Q4 2021 Feb 10, 2022	BUY	$132.01 - $190.29 $287,517 - $414,451	2,178 Added 6.0%	38,455 $5.64 Million
Q3 2021 Nov 12, 2021	SELL	$132.13 - $177.45 $123,145 - $165,383	-932 Reduced 2.5%	36,277 $6.42 Million
Q2 2021 Aug 05, 2021	SELL	$144.0 - $179.73 $1.72 Million - $2.14 Million	-11,934 Reduced 24.28%	37,209 $6.01 Million
Q1 2021 May 06, 2021	SELL	$158.92 - $221.61 $738,978 - $1.03 Million	-4,650 Reduced 8.64%	49,143 $8.42 Million
Q4 2020 Feb 10, 2021	BUY	$162.05 - $240.27 $1.09 Million - $1.61 Million	6,715 Added 14.26%	53,793 $11.8 Million
Q3 2020 Nov 12, 2020	SELL	$113.26 - $167.27 $1.09 Million - $1.61 Million	-9,597 Reduced 16.93%	47,078 $7.82 Million
Q2 2020 Aug 13, 2020	BUY	$72.01 - $120.39 $1.11 Million - $1.85 Million	15,398 Added 37.3%	56,675 $6.47 Million
Q1 2020 May 06, 2020	BUY	$69.78 - $116.21 $230,762 - $384,306	3,307 Added 8.71%	41,277 $3.17 Million
Q4 2019 Feb 05, 2020	BUY	$70.76 - $128.86 $174,423 - $317,639	2,465 Added 6.94%	37,970 $4.89 Million
Q3 2019 Oct 23, 2019	BUY	$77.91 - $109.6 $156,988 - $220,844	2,015 Added 6.02%	35,505 $2.77 Million
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $364,435 - $641,453	6,126 Added 22.39%	33,490 $3.45 Million
Q1 2019 May 01, 2019	BUY	$43.65 - $78.95 $49,018 - $88,660	1,123 Added 4.28%	27,364 $2.01 Million
Q4 2018 Jan 31, 2019	BUY	$32.0 - $47.43 $300,320 - $445,130	9,385 Added 55.68%	26,241 $1.11 Million
Q3 2018 Nov 07, 2018	BUY	$47.1 - $62.7 $4,050 - $5,392	86 Added 0.51%	16,856 $794,000
Q2 2018 Aug 06, 2018	BUY	$26.05 - $52.4 $436,858 - $878,748	16,770 New	16,770 $827,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account